Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 717 results for diabet*

  1. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

  2. Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)

    This guidance has been updated and replaced by NICE guideline NG19.

  3. Type 2 diabetes: The management of type 2 diabetes (CG87)

    This guidance has been updated and replaced by NICE guideline NG28.

  4. Diabetes in pregnancy: Management of diabetes and its complications from pre-conception to the postnatal period (CG63)

    This guidance has been updated and replaced by NICE guideline NG3.

  5. Type 2 diabetes (CG66)

    This guidance has been updated and replaced by NICE guideline NG28.

  6. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued [GID-HST10038]

  7. Peezy Midstream for urine collection (MT446)

    In development [GID-MT538] Expected publication date: TBC

  8. Diabetic foot problems: Inpatient management of diabetic foot problems (CG119)

    This guidance has been updated and replaced by NICE guideline NG19.

  9. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)

    This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.

  10. 3C Patch System for treating diabetic foot ulcers (MIB230)

    This advice has been updated and replaced by NICE medical technologies guidance 66.

  11. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

  12. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  13. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

  14. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.